Active, not recruitingPhase 2NCT04703192
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
Studying Adult T-cell leukemia/lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Daiichi Sankyo
- Principal Investigator
- Global Clinical LeaderDaiichi Sankyo
- Intervention
- Valemetostat Tosylate(drug)
- Enrollment
- 155 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2027
Study locations (30)
- City Of Hope National Medical Center, Duarte, California, United States
- Stanford University Medical Center - Cancer Clinical Trials Office - ONCOLOGY, Palo Alto, California, United States
- University of California San Francisco, San Francisco, California, United States
- University Of Colorado Cancer Center, Aurora, Colorado, United States
- Emory University Hospital - Winship Cancer Institute, Atlanta, Georgia, United States
- Northwestern University - Feinberg School of Medicine, Chicago, Illinois, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Mayo Clinic - Rochester, Rochester, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Hackensack University Medical Center - John Theurer Cancer Center, Hackensack, New Jersey, United States
- Memorial Sloan-Kettering Cancer Center at Memorial Hospital, New York, New York, United States
- Weill Cornell Medicine, New York, New York, United States
- Duke Cancer Center, Durham, North Carolina, United States
- University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
- Epworth Healthcare, Richmond, Australia
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04703192 on ClinicalTrials.govOther trials for Adult T-cell leukemia/lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07388563Azacitidine and Abatacept in Relapsed or Refractory T-Cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT05745714HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesPrincess Maxima Center for Pediatric Oncology
- RECRUITINGPHASE2NCT07159620Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like PatientsThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE1NCT07108868A Phase I Dose Finding Study of MB-CART2219.1University Hospital Tuebingen
- RECRUITINGNCT05237986Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell TherapyNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT07008885BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALLChinese PLA General Hospital
- ACTIVE NOT RECRUITINGPHASE3NCT07541755PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALLFujian Medical University Union Hospital
- RECRUITINGPHASE2NCT06698003A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1Memorial Sloan Kettering Cancer Center